The Philips (VeriSight) Intracardiac Echocardiography (ICE) Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- Philips Clinical & Medical Affairs Global
- Enrollment
- 155
- Locations
- 5
- Primary Endpoint
- Technical Success
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of this observational registry is to report real-world safety and performance of VeriSight for ultrasound guided ICE imaging in percutaneous cardiac intervention procedures when used in standard clinical practice.
Detailed Description
This is a prospective, multi-center, observational, single-arm registry intended to gather real-world data to report VeriSight ICE catheter performance and safety. It will be conducted in the United States under the approval of one or more recognized institutional review boards and in compliance with Good Clinical Practice guidelines defined in International Standards Organization:14155;2011, the Declaration of Helsinki, and all applicable federal and local laws and regulations. Only on label uses of the VeriSight ICE catheter will be allowed. No specific claims are being validated during this registry, though data analyzed from this protocol are intended to inform of future claims regarding the performance and safety of the VeriSight catheter. Enrolled patients will be imaged with VeriSight for various types of percutaneous cardiac interventional procedures. Enrolled subjects will be followed until discharge or ≤48 hrs post-procedure. The registry has a planned duration of approximately 24-36 months with interim analysis planned at 100 patients before further enrollment will be considered. Statistical hypotheses are not intended for this registry and descriptive analysis will be conducted. Data from all clinical sites are intended to be pooled for analysis. It is possible that sub-analyses may be conducted to demonstrate VeriSight guidance for target intervention types in structural heart and electrophysiology procedures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age and willing to provide written, dated and signed, informed consent
- •Scheduled for a procedure that is within the scope of clinical indication for VeriSight per Instructions for Use (IFU)
Exclusion Criteria
- •Contraindicated for ICE catheter placement or patient considerations that make placement of VeriSight not technically feasible
- •If alternate access (as needed instead of femoral) is not viable
- •Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease.
Outcomes
Primary Outcomes
Technical Success
Time Frame: During procedure
Investigator's assessment (Y/N) on successful delivery of VeriSight to the target intracardiac position and sustained device operation during the procedure
Imaging Success
Time Frame: During procedure
Adequate image quality via Likert scale ( Acceptable or better) as determined by the investigator
Clinical Success
Time Frame: During procedure
Investigator's assessment (Y/N) on adequacy of VeriSight imaging for visualization of major cardiac structures, and guiding procedural intervention, and ability to detect/ assess intra-procedural complications.
Number of Participants With Device-related Adverse Event Detection
Time Frame: Procedure through 48 hours or discharge, whichever is earlier
Detect device-related adverse events periprocedural through discharge or ≤48 hours post-procedure, whichever is earlier.